The Duke Human Vaccine Institute was selected to join the Collaborative Influenza Vaccine Innovation Centers (CIVICs) in all three components of the research program, funded by the National Institute of Allergic and Infectious Diseases through the Division of Microbiology and Infectious Diseases.

The CIVICs program aims to improve the durability of seasonal influenza vaccines and develop a universal influenza vaccine through iterative vaccine design, pre-clinical animal studies, and early phase clinical trials.